You are here

High Density Bioprocessing of hPSCs

Several human pluripotent stem cell (hPSC)‐based therapy concepts have now progressed toward first‐in‐man studies. Recent articles have highlighted the urgent need for efficient culture processes to firstly provide the required quantity and quality of hPSCs and secondly promote their clinical translation under commercially viable conditions. Now, a new STEM CELLS Translational Medicine article from Felix Manstein and Robert Zweigerdt (Hannover Medical School, Germany) reports on the combination of instrumented stirred tank bioreactor technology with the power of in silico process modeling to overcome substantial hPSC‐specific hurdles and promote their mass production.